Clinical Rheumatology

, Volume 37, Issue 4, pp 1107–1110 | Cite as

Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment

Brief Report

Abstract

Reports about immune-related adverse events (IrAEs) induced by immune checkpoint inhibitors (ICIs) have been increasing. Although the importance of understanding joint involvement and myalgia as an IrAE has grown, little is known about its characteristics. The aim of this study was to investigate the incidence and clinical characteristics of articular IrAEs. We reviewed 133 patients who were treated with ICIs in our institution and referred to our rheumatologic. Among them, 2 (1.5%) developed arthritis during the use of anti-PD-1 inhibitor, and there was one patient with joint pain after anti-PD-L1 inhibitor who was referred to our department from another institution. No patients had antecedent inflammatory arthritis or any relevant medical history. All 3 patients were negative for anti-nuclear antibody, rheumatoid factor, and anti-cyclic citrullinated peptide antibody. The ultrasonography showed tenosynovitis and enthesitis in both small and large joints with no or insignificant synovitis. Joint pain improved gradually within 6 months with only NSAIDs in 2 patients, and disappeared quickly in the other patient 2 weeks after 20 mg/day of predonisolone. Our report suggested diverse phenotypes of joint involvement and highlighted the importance of accumulating such patients.

Keywords

Arthritis Immune checkpoint inhibitors Immune-related adverse events Ultrasonography 

Notes

Compliance with ethical standards

This investigation was approved by the ethics committee (Ethics Committee of Keio University School of Medicine, approval number: 20110136). Informed consent from the patients was waived according to the regulations in Japan.

Disclosures

None.

References

  1. 1.
    Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168CrossRefPubMedGoogle Scholar
  2. 2.
    Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11:e0160221CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473–486CrossRefPubMedGoogle Scholar
  4. 4.
    Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13:755–763CrossRefPubMedGoogle Scholar
  5. 5.
    Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H, Atagi S, Fujita S, Tanaka H, Takeda K, Satouchi M, Namba Y, Tamura T (2017) Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 104:111–118CrossRefPubMedGoogle Scholar
  6. 6.
    Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cappelli LC, Shah AA, Bingham CO III (2016) Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open 2:e000321CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Calabrese L, Velcheti V (2017) Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis 76:1–3CrossRefPubMedGoogle Scholar
  9. 9.
    Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 69:1751–1763CrossRefGoogle Scholar
  10. 10.
    Chan MM, Kefford RF, Carlino M, Clements A, Manolios N (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38:37–39CrossRefPubMedGoogle Scholar
  11. 11.
    Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Hanque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50CrossRefPubMedGoogle Scholar
  12. 12.
    Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747–1750CrossRefPubMedGoogle Scholar
  13. 13.
    van der Vlist M, Kuball J, Radstake TRD, Meyaard L (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol 12:593–604CrossRefPubMedGoogle Scholar
  14. 14.
    González-Rodríguez E, Rodríguez-Abreu D (2016) Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21:804–816CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Internal MedicineKeio University School of MedicineTokyoJapan

Personalised recommendations